Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l -dopa using rAAV-mediated gene transfer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Intrastriatal delivery of the tyrosine hydroxylase gene by viral vectors is being explored as a tool for local delivery of l -dopa in animals with lesions of the nigrostriatal pathway. The functional effects reported using this approach have been disappointing, probably because the striatal l -dopa levels attained have been too low. In the present study, we have defined a critical threshold level of l -dopa, 1.5 pmol/mg of tissue, that has to be reached to induce any significant functional effects. Using new generation high-titer recombinant adeno-associated virus vectors, we show that levels of striatal l -dopa production exceeding this threshold can be obtained provided that tyrosine hydroxylase is coexpressed with the cofactor synthetic enzyme, GTP-cyclohydrolase-1. After striatal transduction with this combination of vectors, substantial functional improvement in both drug-induced and spontaneous behavior was observed in rats with either complete or partial 6hydroxydopamine lesions of the nigrostriatal pathway. However, complete reversal of motor deficits occurred only in animals in which part of the striatal dopamine innervation was left intact. Spared nigrostriatal fibers thus may convert l -dopa to dopamine and store and release dopamine in a more physiologically relevant manner in the denervated striatum to mediate better striatal output-dependent motor function. We conclude that intrastriatal l -dopa delivery may be a viable strategy for treatment and control of adverse side effects associated with oral l -dopa therapy such as on-off fluctuations and drug-induced dyskinesias in patients with Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adeno-associated virus general transduction vectors: analysis of proviral structures
McLaughlin, S. K., Collis, P., Hermonat, P. L., & Muzyczka, N. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1963-1973.1988 · Cited by 348
Self-citationViral Gene Delivery Selectively Restores Feeding and Prevents Lethality of Dopamine-Deficient Mice
Szczypka, M. S., Mandel, R. J., Donahue, B. A., Snyder, R. O., Leff, S. E., & Palmiter, R. D. (1999) · Neuron · doi:10.1016/s0896-6273(00)80688-1 · Cited by 129
Self-citation
Cited by
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
Self-citationToxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739
Neurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 506
A Guide to Neurotoxic Animal Models of Parkinson's Disease
Tieu, K. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009316 · Cited by 483
Meck, W. H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.06.031 · Cited by 354
Lastres-Becker, I., Ulusoy, A., Innamorato, N. G., Sahin, G., Rábano, A., Kirik, D., & Cuadrado, A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds143 · Cited by 263
Self-citationZhang, Y., Calon, F., Zhu, C., Boado, R. J., & Pardridge, W. M. (2003) · Human Gene Therapy · doi:10.1089/10430340360464660 · Cited by 194
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186
Parish, C. L., Castelo-Branco, G., Rawal, N., Tonnesen, J., Sorensen, A. T., Salto, C., Kokaia, M., Lindvall, O., & Arenas, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32273 · Cited by 179
Early synaptic dysfunction in Parkinson's disease: Insights from animal models
Schirinzi, T., Madeo, G., Martella, G., Maltese, M., Picconi, B., Calabresi, P., & Pisani, A. (2016) · Movement Disorders · doi:10.1002/mds.26620 · Cited by 160
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“Therapeutic benefits in PD models following AAV-mediated transfer of TH and/or GTPCH1 are currently being investigated with co-delivery of TH and GTPCH1 resulting in the highest levels of striatal dopamine and alleviation of PD symptoms (Kirik et al. 2002; Leff et al. 1999; Mandel et al. 1998; Muramatsu et al. 2002; S…”
BackgroundSun, M., Kong, L., Wang, X., Lu, X.-G., Gao, Q., & Geller, A. I. (2005) · Brain Research · doi:10.1016/j.brainres.2005.05.072 · Cited by 154
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Tetrahydrobioterin (BH4) pathway: from metabolism to neuropsychiatry
Fanet, H., Capuron, L., Castanon, N., Calon, F., & Vancassel, S. (2021) · Current Neuropharmacology · doi:10.2174/1570159x18666200729103529 · Cited by 134
Recombinant Adeno-Associated Viral Vectors in the Nervous System
Burger, C., Nash, K., & Mandel, R. J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.781 · Cited by 110
Self-citation
Metadata
- Authors
- Kirik, D., Georgievska, B., Burger, C., Winkler, C., Muzyczka, N., Mandel, R. J., & Björklund, A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-03-26
- Volume
- 99
- Issue
- 7
- Pages
- 4708-4713
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1977376243
- Cited by
- 140
- References
- 2
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.